News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
256,356 Results
Type
Article (13723)
Company Profile (256)
Press Release (242377)
Section
Business (79145)
Career Advice (149)
Deals (13163)
Drug Delivery (28)
Drug Development (50143)
Employer Resources (31)
FDA (5633)
Job Trends (5103)
News (143572)
Policy (10010)
Tag
Academia (900)
Africa (145)
Allergies (30)
Alliances (21402)
Alzheimer's disease (685)
Antibody-drug conjugate (ADC) (31)
Approvals (5598)
Arizona (38)
Artificial intelligence (29)
Asia (16640)
Australia (2780)
Bankruptcy (96)
Best Places to Work (4347)
Biotechnology (214)
C2C Services and Suppliers (10603)
California (1224)
Canada (499)
Cancer (302)
Career advice (130)
CAR-T (33)
Cell therapy (95)
China (90)
Clinical research (39043)
Collaboration (85)
Colorado (38)
Compensation (40)
Connecticut (42)
COVID-19 (978)
Cystic fibrosis (58)
Data (226)
Diabetes (38)
Diagnostics (1157)
Earnings (28354)
Employer resources (29)
Europe (35684)
Events (45769)
Executive appointments (98)
FDA (5749)
Florida (122)
Funding (98)
Gene editing (28)
Gene therapy (81)
GLP-1 (263)
Government (1051)
Healthcare (6510)
Hotbed/Location (184111)
Illinois (74)
Indiana (43)
Infectious disease (988)
Inflammatory bowel disease (79)
IPO (7134)
Job creations (856)
Job search strategy (124)
Kansas (52)
Layoffs (177)
Legal (1369)
Lung cancer (70)
Manufacturing (28)
Maryland (185)
Massachusetts (994)
Medical device (2514)
Medtech (2515)
Mergers & acquisitions (6034)
Metabolic disorders (132)
Michigan (38)
Minnesota (65)
Neuroscience (793)
New Jersey (331)
New York (396)
NextGen Class of 2024 (1975)
Non-profit (837)
North Carolina (326)
Northern California (532)
Obesity (76)
Ohio (62)
Opinion (86)
Parkinson's disease (31)
Patents (36)
Pennsylvania (276)
People (24699)
Pharmaceutical (41)
Phase I (13696)
Phase II (18158)
Phase III (11549)
Pipeline (77)
Postmarket research (842)
Preclinical (5767)
Press Release (30)
Rare diseases (102)
Real estate (1405)
Regulatory (8018)
Research institute (928)
South America (206)
Southern California (508)
Startups (1963)
Texas (114)
United States (4679)
Vaccines (132)
Washington State (154)
Weight loss (59)
Date
Today (52)
Last 7 days (421)
Last 30 days (1388)
Last 365 days (21428)
2024 (15082)
2023 (22412)
2022 (26822)
2021 (27806)
2020 (23357)
2019 (16225)
2018 (11738)
2017 (13746)
2016 (11839)
2015 (14349)
2014 (10392)
2013 (7484)
2012 (7532)
2011 (7614)
2010 (7428)
256,356 Results for "edgewise therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
Edgewise Therapeutics Appoints Arlene Morris to its Board of Directors
Edgewise Therapeutics, Inc. announced the appointment of biotechnology industry veteran Arlene Morris to its Board of Directors.
May 7, 2024
·
2 min read
Business
Edgewise Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today reported financial results for the first quarter of 2024 and recent business highlights.
May 9, 2024
·
17 min read
Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 15, 2024
Edgewise Therapeutics, Inc. today announced that management will present at the RBC Capital Markets Global Healthcare Conference on Wednesday, May 15, 2024, at 3:35 pm ET.
May 10, 2024
·
1 min read
Drug Development
Edgewise Therapeutics Doses First Patient in Phase 2 CIRRUS-HCM Trial of EDG-7500 in Obstructive Hypertrophic Cardiomyopathy (HCM)
Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced the dosing of the first patient in the Phase 2 CIRRUS-HCM trial of EDG-7500.
May 6, 2024
·
8 min read
Edgewise Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium on April 2, 2024
Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that management will present at the Cantor Virtual Muscular Dystrophy Symposium on Tuesday, April 2, 2024, at 2:20 pm ET.
March 27, 2024
·
1 min read
Edgewise Therapeutics to Present at the Leerink Partners Global Biopharma Conference on March 11, 2024
Edgewise Therapeutics, Inc. today announced that management will present at the Leerink Partners Global Biopharma Conference on Monday, March 11, 2024, at 12:00 pm ET.
March 5, 2024
·
1 min read
Edgewise Therapeutics Announces Upcoming Podium Presentation at the American College of Cardiology’s 2024 Annual Scientific Session
Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that the Company will present data on EDG-7500 at the American College of Cardiology’s Annual Scientific Session (ACC.24).
March 28, 2024
·
3 min read
Business
Edgewise Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today reported financial results for the fourth quarter and full year of 2023 and recent business highlights.
February 22, 2024
·
16 min read
Deals
Edgewise Therapeutics Announces Pricing of $240 Million Underwritten Offering of Common Stock
Edgewise Therapeutics, Inc. today announced the pricing of an underwritten offering of 21,818,182 shares of its common stock at an offering price of $11.00 per share.
January 19, 2024
·
4 min read
Press Releases
Edgewise Therapeutics Announces Positive Top-Line Data from Phase 1 Trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy (HCM)
September 19, 2024
·
9 min read
1 of 25,636
Next
